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Phenobarbital for childhood epilepsy: systematic review
Deb K Pal
Department of Psychiatry, Department of Epidemiology, and Division of Statistical Genetics,
Mailman School of Public Health, Columbia University, New York, NY, USA
Abstract
Introduction—Against a background of concern about the safety of new pharmaceutical products,
there has been renewed interest in one of the oldest antiepileptic drugs (AEDs), phenobarbital.
Although still in widespread use in developing countries, its popularity has slipped in Western
countries over the past century, partly because of controversy about its adverse effect profile. This
critical review examines the evidence supporting its effectiveness and its associated behavioural
adverse effects for febrile convulsions and childhood epilepsy.
Methods—Relevant randomised controlled trials (RCTs) of phenobarbital vs other antiepileptic
drugs or placebo between 1970-2005 were identified through a comprehensive manual and computer
database search of the world biomedical literature. Eleven RCTs of febrile convulsions and nine
RCTs of childhood epilepsy were systematically reviewed against a conventional set of quality
criteria.
Results—With a few exceptions, the overall quality of clinical trial methodology, especially in the
early studies conducted in the 1970s and 1980s, was poor. There is no evidence for a difference in
antiepileptic efficacy between phenobarbital and any other compared AED, yet no evidence for
absolute efficacy. No convincing evidence exists for an excess of behavioural adverse effects, over
other AEDs, attributable to phenobarbital. Masked studies of phenobarbital in childhood epilepsy
have shown no significant differences in behavioural or cognitive adverse effects compared to other
AEDs. This is in contrast to the excess of such adverse effects reported in studies open to observer
bias. However, the one finding of reduction in cognitive ability associated with phenobarbital
treatment for febrile convulsions remains a concern. Future areas of clinical and genetic
epidemiological research are outlined.
Keywords
phenobarbital; systematic review; randomised controlled trial; efficacy; adverse effects; childhood;
epilepsy; febrile convulsion
Introduction
There has been a resurgence of clinical interest in the role of phenobarbital (PB) for treating
childhood epilepsy in Western countries. In 1912, PB became one of the first agents used
against epilepsy1 and is now the most widely used anti-epileptic drug (AED) in the world. Its
low cost and accepted use for a wide range of seizure types has led to its position as the World
Health Organization's first-line AED in developing countries.
In Western countries, PB has been in and out of favour as an AED. Although widely used as
a prophylactic against febrile seizures in the 1960s and 1970s, concerns about its
neurobehavioural adverse effect profile2 led to a decline in its use for all seizure disorders.
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More than a decade after it was in vogue, a meta-analysis of its effectiveness as a febrile seizure
prophylactic concluded no advantage over placebo3. The pooled odds ratio (OR) of British
clinical trials demonstrated no significant protection from either phenobarbital OR 0.8 (CI
0.53–1.20) or sodium valproate OR 1.42 (CI 0.85–2.36).
A flurry of uncontrolled observational studies from the 1970s and 1980s, claiming excessive
behavioural adverse effects, had a strongly negative effect on prescribing behaviour, even in
research circles. For example, in the MRC Anticonvulsant Trial started around 19804, PB was
withdrawn from the children's trial arm as a result of perceived adverse behavioural effects
and because it was believed that inclusion of PB was hampering recruitment. The evidence for
PB's excessive adverse effects was never examined in critical detail. Thus PB's role in the
antiepileptic armamentarium remains controversial. Now, approaching its centenary, PB has
once again been hailed as an AED of promise5.
The reasons for renewed interest in this tried and tested “old” drug arise mainly from doubts
about the safety of newly licensed pharmaceuticals, and public disquiet over the unsatisfactory
regulatory framework for preclinical evaluation of new medicines, particularly for children6.
Financial settlements to patients harmed by COX-2 inhibitors7, and of course the controversies
about risk-benefit profiles associated with felbamate8 and vigabatrin9, are stimulating
clinicians to take a more conservative approach toward new treatments, and to re-evaluate older
drugs that have suffered from “commercial neglect”10. Cost of treatment may also be a
consideration: carbamazepine costs around ten times, and lamotrigine almost forty times as
much as the equivalent dose of PB11.
Now that prescribing fashion is turning back towards PB, it is an opportune moment to
reevaluate the original controversy surrounding PB, and be sure that today PB is prescribed in
accordance with the evidence for its efficacy and tolerability. In this paper therefore, we ask:
(i) to what extent the original concerns about PB were justified; (ii) given the current
understanding of PB's neurobehavioural adverse effect profile, what are the most promising
areas for its use in wealthy and poor societies; and (iii) what research questions need to be
addressed to realise more of its commercial potential?
Methods
The methodology of a systematic review has been used to evaluate pertinent studies. Systematic
reviews are a useful way to weigh research evidence, especially when there are conflicting
results, when there is possible heterogeneity in the study parameters, and when no single trial
is adequately designed to define best clinical practice. Randomised controlled trials (RCTs)
have been chosen as the basis for this systematic review because observational studies are
limited by bias and uncontrolled confounding factors. RCTs provide the best quality of
evidence for clinical decision-making. RCTs of PB for childhood epilepsy or febrile
convulsions were identified by the Cochrane search strategy12. These trials were
systematically assessed on criteria of design and reporting quality (meeting or not meeting
criteria, or unclear). Criterion referenced assessment is commonplace in meta-analysis and
systematic reviews13. Studies including both afebrile and febrile seizures were included in the
review because many of the conclusions about paediatric tolerability were made from studies
of PB in febrile seizures.
Study selection criteria
All RCTs of AEDs involving phenobarbital as continuous (maintenance) oral monotherapy
versus placebo, no treatment or other active drugs were included. Quasi-randomised studies,
e.g. treatment assigned on the basis of day of admission or birth date, were excluded because
of the possibility of selection bias. Subjects had to include young people or children, as defined
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by the authors, with clinically diagnosed generalised tonic-clonic or focal epilepsy or febrile
convulsions. Papers reporting the use of PB for seizures in the context of infectious illness
were not included14. Behavioural problems were defined variously by the authors to include
parental reports of hyperactivity, “hyperagility”, overactivity, hyperkinesia, listlessness,
irritability, aggressiveness, emotional instability, “unpleasant behaviour”, temper tantrums,
fussiness, paradoxical excitation and agitation. Only a few studies used validated behavioural
instruments to measure outcome.
Search strategy
Papers were identified through the Cochrane Epilepsy Group Register of Clinical Trials in
Epilepsy; the Cochrane Library; computer database search of MEDLINE, EMBASE,
SCISEARCH, PSYCHLIT between 1969 and 2005 in all languages, using keywords and
strategies developed by the Cochrane Epilepsy Group; review articles; chapters in books;
citation search; reference lists of all papers identified by the search; lastly, certain authors were
approached for knowledge of unpublished trials. Abstracts of potential studies were reviewed
for inclusion. Very few RCTs of AEDs were carried out before 197015 and therefore this period
was not included. Data were extracted from published studies using the proforma in Tables 1
and 2.
Quality criteria
Trials were judged according to the reporting of treatment assignment, blinding, follow-up
completeness, and method of analysis. Similar criteria have been used in other systematic
reviews, with the rationale that poorly designed or conducted clinical trials are open to bias,
random error and confounding and therefore should be interpreted with caution16.
Results – febrile convulsions
Febrile convulsions are a mainly benign group of seizures, common (5%) in early childhood.
Associated with febrile illnesses, most children who have one febrile seizure have only the one
or two (infrequently more) febrile convulsions in the first six years of life. Up to 10% may later
have afebrile seizures, but there is no evidence that treating febrile convulsions with AEDs
prevents later epilepsy. In the 1960s and 1970s there was a vogue for prophylactic treatment
of febrile convulsions with AEDs, principally PB. This practice was more common in the US
than in Europe.
Sixteen trials were identified, of which five did not meet entry criteria because of non-random
treatment assignment17-21. Fourteen reports from the 11 remaining trials are summarised in
Table 1. Of these 11 trials, five used masked assessments and six were unmasked. Four of the
five masked trials studied behavioural side-effects and showed no differences compared to
placebo or intermittent diazepam. The fifth showed an important long term deficit in cognitive
outcome in the PB group22. Four of the six unmasked trials studied behavioural side-effects:
two showed an excess of behavioural side effects with PB compared to either valproate or no
treatment23-25 and two showed no difference compared with phenytoin or rectal
diazepam26,27. The studies are described below.
Wolf et al. compared three regimens: continuous PB, intermittent PB or no treatment in children
with febrile seizures. The results for seizure recurrence, behavioural effects and cognitive
function were reported separately and have had a considerable influence on subsequent clinical
practice both regarding the use of PB and prophylaxis of febrile convulsions23,24,28. The main
study randomised 355 children into three groups and followed them up over a mean period of
28 months (m). The design allowed children on no treatment to convert to the active treatment
group. Seven of 106 (7%) in the continuous PB group had a seizure recurrence during one year
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of follow up compared to 20/249 (8%) in the intermittent and no treatment groups. After
adjusting for duration of follow-up, this difference was reported to be significant although
neither point estimate nor confidence intervals for this difference were given, and durations of
follow-up were not reported for each group.
The study also reported 46/109 (42%) of treated children developing behavioural problems
compared to 21/120 (18%) in the no-treatment group24. Sixteen per cent of those on continuous
treatment dropped out early because of hyperactivity but no data were presented on the
proportions in the other groups dropping out, so it was difficult to assess if dropout was related
to treatment group. Behaviour was assessed only by parental report and neither parent nor
physician was blind to treatment status. It was also notable that there was resistance from
parents to accept continuous PB treatment, some refusing to enter that arm of the study because
of knowledge of side effects. This obviously raises the question of bias in assessing outcome.
Also, the effect of tablet administration alone on child behaviour was not adequately measured
by the nil treatment group, and it was not clear whether results were presented for all subjects
who had entered the trial or if only completers were studied. Interestingly, the only significant
predictor of behavioural problems in both treatment arms was the existence of preexisting
behavioural problems.
In a subsequent study, Wolf et al. compared cognitive function in 25 children completing the
study on PB to 25 not on treatment28. It was not clear how these subjects had been selected
from the larger group. There were no differences in IQ by the Wechsler Preschool Inventory
(WPPSI) scale either just before stopping or three months after stopping therapy. However,
the study had selected children who completed the trial, and who would be less likely to have
neurobehavioural side effects, and more likely to come from well-motivated families. Both
factors would not have been revealed by baseline comparison and would have biased the results
by diminishing differences between treatment and control groups. Also there was no baseline
comparison of IQ, so it was possible that the groups were not comparable to begin with. In
summary, Wolf et al.'s studies were seriously affected by bias from not using an intention to
treat analysis, by lack of blinding, by the absence of a placebo group, by not reporting follow-
up in control groups, and by non-random selection of children for cognitive testing. Neither
protection against recurrent febrile convulsions nor excessive serious behavioural effects of
PB can be concluded from these studies.
Camfield conducted a double-blind, placebo controlled comparison of PB and placebo for
febrile convulsions29. Follow-up was over 12 m with 70% of 65 subjects completing that
period. Outcome was assessed by parental report of behaviour and standardised psychological
testing. There were no physician or parent reported episodes of hyperactivity, and no significant
differences in emotional state or cognitive function between the two groups at outcome.
Subgroup analysis suggested a reduction in the memory subscale for children on PB, and for
a fall in comprehension between 8 m and 12 m testing, but the confidence intervals for this
reduction were not reported. A follow-up report of 79 children showed that 5.1% of the PB
group had recurrence compared with 25% of those treated with placebo30.
Ngwane and Bower compared the efficacy of PB and sodium valproate for the prevention of
simple febrile convulsions31. Allocation of active treatments was randomised but a no
treatment group was created by default through parental or physician refusal to enter the trial,
introducing selection bias. Treatment status was double-blind over 12 m, with four drop-outs
owing to side effects equally distributed between the treatment groups. Analysis was by χ2 test
between the three groups, showing fewer seizure recurrences in active compared to no
treatment groups, but no difference in recurrences between the two active treatments. Since
the control group was not randomly selected, and did not receive placebo treatment, it was not
valid to conclude a preventive effect for either drug.
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Bacon et al. investigated the efficacy of PB and phenytoin against placebo26. Allocation was
randomised but blinding failed because phenytoin could not be administered successfully as a
capsule, whilst PB and placebo were given as capsules. After 12 m, 69 of 207 had dropped out
but no information was given relating to dropout and initial treatment allocation, introducing
possible selection bias into the assessment of outcome. There were no differences in recurrence
rates. However, the authors claimed a significant protective effect against seizure recurrence
in a subgroup (those with PB salivary levels > 8 mg/l) of a subgroup (children < 14 m) – a total
of 10 children. This type of subgroup analysis of compliers is neither convincing nor does it
have clinically useful implications. In a parallel study, the authors compared behavioural side
effects of 56 children in the three study groups and found no differences in incidence of
behavioural problems between the study arms26. However, they used an unvalidated
questionnaire which might not have been sensitive enough to detect clinically important
differences.
McKinlay and Newton compared the efficacy of PB and sodium valproate for preventing
recurrence in children at increased risk of recurrent febrile convulsions25. Subjects were
randomised to continuous treatments or intermittent rectal diazepam. 151 children were
followed for an average of two years, 13% dropped out. The trial, which was analysed on an
intention to treat basis, found no significant reduction in recurrence from any intervention. The
odds ratio of effect for sodium valproate was 2.19 (95% CI: 0.96–5.0) and for PB was 1.36
(95% CI: 0.55–3.34) relative to the diazepam group. Eight of 41 children had their PB stopped
by parents because of side effects, compared to three of 50 in the valproate group.
Lee and Melchior compared efficacy of PB and sodium valproate after a first febrile
seizure32. A group of children whose parents refused treatment was selected as controls. The
trial was not blinded and the primary outcome of seizure recurrence was examined at 12 m by
comparing compliers only by χ2 test using one sided p values. The authors concluded a
beneficial effect for sodium valproate over the no treatment group, but this was not justified
since compliers were being compared to a selected control group. They also concluded PB to
be ineffective in preventing recurrence and for sodium valproate to be significantly more
effective. However, no confidence intervals were presented, and if the analysis was repeated
using conventional two-sided P values and intention to treat data, then the difference between
the two active treatments would not be significant at the 5% level.
Anthony and Hawke randomised children with recurrent febrile seizures to PB or
carbamazepine to study their relative efficacy33. Almost half of their subjects were excluded
from analysis because of loss to follow-up, low AED levels or side effects. The investigators
were supposedly blind to the treatments although the treating clinician was not blinded and the
tablets were readily identifiable by parents. The method of assessing side effects was not given.
With so many subjects lost to follow-up, and only analysing compliers, it was impossible to
endorse the authors' conclusion that PB was more effective than carbamazepine in preventing
febrile convulsions. Neither was it valid to comment on side effects when blinding was not
effective.
Mamelle et al. compared sodium valproate, PB and placebo in 67 subjects randomised to
treatment for an average of 24 m34. In all, there was one recurrence in the valproate group of
22 subjects (4.5%), 4/21 in the PB group (19%) and 14/26 (35%) in the placebo group.
Monitoring was by a doctor aware of treatment status. Parents however, were unaware of the
name of the medication. There were five children reported to have agitation on PB, and no side
effects with either valproate or placebo were reported. The relation of side effects to dropout
was unknown, there being one in the valproate and placebo group and two in the PB group.
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Garcia et al. conducted a study similar in design to that of McKinlay, comparing continuous
PB with intermittent rectal diazepam27. One hundred children, randomised to either treatment,
were followed up over 18 m for seizure recurrence and side effects. 10% of the PB treated
children had a recurrence compared with 8% of the diazepam group. Side effects were similar,
the authors reporting three (6%) poorly tolerating PB because of hyperactivity (necessitating
change to sodium valproate) compared to five (10%) with drowsiness in the diazepam group.
Farwell et al. conducted a large randomised, placebo controlled, double-blind study of PB for
febrile seizures22. 80% of 217 subjects completed two year follow up. The primary outcomes
were seizure recurrence and IQ assessment by the Stanford-Binet scale. Cox multiple
regression was used, controlling for baseline variables, and using intention to treat analysis,
and this showed an eight point deficit on the Stanford-Binet scale after two years of treatment,
a deficit persisting for 6 m after discontinuation of therapy22. There was no significant decrease
in the recurrence rate of febrile seizures on treatment compared to placebo. Parents of children
on PB reported more behavioural problems in the first six weeks, but there were no differences
compared to the placebo group after two years. A small difference might have been diluted by
crossover of 25% of the placebo group to PB by the end of the study.
Hirtz et al. investigated sleep disturbance in a double blind, randomised, placebo controlled,
crossover study of PB versus placebo35. They demonstrated no increase in sleep disturbance
in toddlers treated with PB for the prevention of febrile seizures, except in those infants who
had exhibited sleep disturbances at the start of treatment. The authors suggested an interaction
between PB treatment and an intrinsic vulnerability for behavioural (sleep) disturbance.
Summary
As well as lack of evidence for efficacy in preventing febrile seizures, the clinical trials above
show a lack of conclusive evidence for an excess of behavioural adverse effects associated
with PB.
Results – childhood epilepsy
Nine clinical trials were identified using the above strategy and all were included for review
(Table 2). Of the nine, six were in Western countries, and three were from developing countries.
Four trials used masked assessments, and none of these showed significant clinical differences
in side effects, although numbers were small. Three trials did not use masked assessments: one
claimed intolerable side effects4, another was too poorly designed and analysed to allow
interpretation36, and the third showed no difference in IQ testing at outcome to other treatment
groups37. None of the trials in developing countries showed a significant difference in side
effects between PB and other active treatments. No trial showed any difference in relative
efficacy. All nine trials are described below in chronological order.
Ozdirim et al. investigated behavioural problems in children with newly diagnosed
epilepsy36. Sixty three children were randomised to PB, phenytoin or placebo. After 3 m, their
scores on four standardised psychological tests and a custom made behaviour questionnaire
were compared by analysis of variance. No details were given of randomisation procedure or
baseline details to verify the efficacy of randomisation. Treatment and assessment were not
blinded and the duration of follow-up was very short. The PB group showed no improvement
in one of three cognitive tests, and children in this group were also reported to have more
behavioural problems. However, there were no differences in performance on other tests of
adaptation and non-verbal performance. This one difference, which was not quantified, might
have been the result of multiple significance testing. The behaviour rating scale was unvalidated
and open to observer bias. The analysis did not allow for the effect of confounding variables
such as age or sex. These flaws make the study results uninterpretable.
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Young et al. compared the behavioural side effects of PB and mephobarbital38. They used a
randomised, double-blind, crossover design with eight subjects over a period of 3 m. Behaviour
was measured by the Conners Parent Rating Scale and the two groups compared by analysis
of variance. No significant deterioration after treatment or difference of behaviour between
treatments was demonstrated. However, with only eight children, assuming that 40% of PB
treated children developed behavioural side effects, the study had a mere 1% power to
demonstrate a risk ratio of 4.0.
Mitchell and Chavez compared the behaviour, cognition and seizure control of 33 non-retarded
children with focal seizures randomised to either PB or carbamazepine39. Cognitive
performance was measured by standard psychological instruments but behaviour was assessed
using an unvalidated, custom made instrument. Parents and the evaluating psychologist were
blind to treatment status. There was no significant difference in seizure control, and no
difference in behaviour or cognitive function between the groups. However, only 19 children
completed the 12 month trial and the power of the study to detect real differences was therefore
quite low.
Vining et al. compared the efficacy and side effects of PB and valproic acid in a double-blind
crossover study of 21 children of normal intelligence with mild seizure disorders, treated for
6 months with each drug40. Vigilance and attention were measured by a neuropsychological
test battery, and behavioural problems assessed using the Conners Parent and Teacher Rating
Scales41. Parents and assessors were both blind to treatment status. Seven children dropped
out, four reportedly because of behavioural problems on PB. Each arm lasted six months and
was analysed, for completers only, by significance testing and analysis of variance between
treatment groups. The drugs were thought to be equally effective in seizure control.
No differences in side effects were noticed in routine clinical assessment but the authors noticed
a tendency for better performance on testing with valproic acid. There were at least 17 tests of
significance used to demonstrate differences on subscales of the Conners Scale and Wechsler
Intelligence Scale for Children. However, there were no preset hypotheses concerning the
subscales expected to be important, and differences in favour of valproic acid could have
occurred by chance either as a result of multiple testing, or due to type I error owing to the
small sample size. Additionally, these differences were not supported by clinical report. This
trial did not therefore show clinically meaningful differences in side effects.
De Silva et al. compared the efficacy of PB, phenytoin, carbamazepine and sodium valproate
in a randomised pragmatic trial of newly diagnosed childhood epilepsy4. Both parents and
physicians knew the identity of the drug after randomisation. There were no significant
differences with regard to efficacy after three years of follow up, 73% achieving one year
remission. Six of ten children randomised to PB were withdrawn because of reported
behavioural side effects. Only four children remained on PB for the duration of the trial. A
total of 15 (9%) of the original sample withdrew because of side effects. The strong possibility
of observer bias limited conclusions about the possible excess of side effects of PB in this
study.
Feksi et al. conducted a clinical trial of adults and children with epilepsy in Kenya, using PB
and carbamazepine42. They showed no difference in efficacy: 52–54% of subjects on either
drug achieving seizure remission at one year and 65% experiencing an improvement in seizure
control. In all, 302 subjects were randomised to either drug, and 82% completed follow-up
over a year. There were similar numbers of withdrawals (26 vs 27) and unacceptable side effects
reported to the clinic psychiatrist or visiting health worker (carbamazepine 8, PB 5) in each
group.
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Placencia et al. conducted a similar randomised study in a community epilepsy control
programme in Ecuador43. 192 adults and children were randomised to PB or carbamazepine.
After 12 m follow-up, 54% of the PB group and 47% of the carbamazepine group achieved
seizure freedom, and there was no difference in the proportions with reduced seizure frequency
between the two groups (60% vs 68%). Side effects were monitored with a checklist throughout
the study, only 5 subjects dropping out because of overt side effects. There were no differences
in the proportion of completers reporting side effects in each treatment arm.
Chen et al. compared cognitive function of newly diagnosed children with epilepsy randomised
to PB, sodium valproate or carbamazepine37. Seventy-six children, with no pre-existing
behaviour problems, were followed up for 12 m measuring outcome with the Chinese version
of the Wechsler Intelligence Scale for Children-Revised and Bender-Gestalt test, as well as
neurophysiological performance in response to auditory tones. No differences were found in
IQ testing at outcome between the groups, but children in the PB group had longer latencies
of electro-physiological response at 6 and 12 m, a finding of uncertain clinical significance.
Pal et al. conducted a RCT of PB vs phenytoin in children aged 2 to 18 yr44. The authors
recruited a population-based sample of untreated children with epilepsy in rural India. 94
children were randomised, using the technique of minimisation to stratify for age group and
cerebral impairments. 62 children (66%) remained on treatment after 12 m, but 82 (87%) of
the original cohort had behavioural outcomes recorded. Intervention was framed in a
community-based rehabilitation setting, including home visits by disability workers. Seizure
outcomes were measured as actuarial (time to first seizure) events, as well as proportion seizure
free at quarterly intervals. Behavioural problems were measured using validated instruments
such as the Conners Scale (CPRS-48), the investigator blinded to treatment status. There were
no differences in efficacy between the two drugs (Hazard ratio: 0.51, 95% CI: 0.16–1.59). 65%
were seizure-free in the final quarter. There were no significant differences in objectively
assessed behavioural problems in either treatment arm, even when adjusted for confounding
variables. There were no significant differences in parent-reported adverse effects.
Summary
None of the nine masked clinical trials of PB, for either the prevention of febrile seizures or
of epilepsy, has shown an excess of behavioural adverse effects over placebo or active
treatment. In comparison, three of 11 unmasked clinical trials have attributed significant
behavioural adverse effects to PB. The quality of evidence from these trials is discussed below.
Discussion
The overall design quality and statistical methodology of clinical trials in this area is poor,
especially for those trials conducted in the 1970s and 1980s. Coatsworth reached similar
conclusions in reviewing the efficacy of AEDs for the era up to 197015. Small sample size and
multiple significance testing may have resulted in missed or false associations, respectively.
Control groups receiving no treatment introduce bias because of the absence of the placebo
effect, exaggerating the magnitude of treatment and side effects. Inadequate randomisation and
the absence of blinding also make selection and observer bias a distinct possibility, leading to
misleading inferences regarding effectiveness and toxicity. Blinding is more feasible in trials
that include only one or two active treatments. Substantial losses to follow-up and the inability
to demonstrate lack of bias in these losses relative to those retained, further reduce the validity
of results. Lastly, the analysis of compliers invalidates the general-isability of findings to the
general population and misses the whole point of randomising to eliminate confounding from
other factors related to staying in treatment45.
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To what extent were the original concerns about PB justified?
The early concerns about PB's adverse effects were largely based on its use in preventing febrile
convulsions in preschool aged infants and children. As shown, careful evaluation of the RCTs
from that era does not provide convincing evidence for an excess of behavioural adverse effects,
over other AEDs, attributable to PB. Overall, masked studies of childhood epilepsy have shown
no significant differences in behavioural or cognitive side effects for PB compared with other
AEDs. This is in contrast to the excess of such side effects reported in studies that are open to
observer bias, i.e. unmasked. An important lesson from this review is the vastly different
conclusions that can be inferred from different classes or quality of evidence. Findings from
febrile convulsion trials are consistent with childhood epilepsy trials, with one important
difference: a significant reduction in learning ability among children treated with PB was
demonstrated22. So far this result has not been replicated or examined in children with
childhood epilepsy, but nevertheless remains a concern. The question remains open whether
cognitive ability is impaired only in children with febrile convulsions, only in preschool
children, or whether there are other important interactions involved. Until this question is
investigated in detail, it is doubtful that PB will be chosen as a first-line agent for childhood
epilepsy in situations where an economically viable alternative exists.
No study has shown a difference in antiepileptic efficacy between PB and other first-line AEDs,
either in Western or developing countries, yet absolute efficacy for epilepsy has not been
proven. There is conflicting evidence about absolute efficacy of PB in preventing febrile
convulsions, but this is a moot finding because prophylactic AEDs have hardly been used in
the clinical management of febrile seizures since the 1970s.
As a general finding, the proportion of behavioural (and other) side effects leading to dropout
from treatment has been lower in developing countries compared to Western studies of
antiepileptic drugs. There may be many explanations for this. Some are simple and related to
study design, e.g. studies may have contained a mixture of adult and child subjects; or varying
dosing schedules may have been used. Behavioural “problems” in children are socio-culturally
defined: most measuring instruments rely on parental or teacher proxy reports of behaviour,
rather than on intrinsic measures of individual's neurophysiological functioning; thus their
prevalence varies considerably both across and within countries. Parents in different countries
may have different thresholds for labelling behaviour as problematic, or may be more or less
inclined to attribute such behaviours to extrinsic agents like drugs.
Within cultures, behavioural problems have a multifactorial basis, with important biological
and socio-cultural risk and protective factors46. Biological factors include age, the peak onset
for attention deficit/hyperactivity disorder being in the preschool years; central neurological
deficit is also a strong risk factor47. However, more recent studies of child behaviour problems
have examined potent risk factors from the environment, including parenting style, social
support etc46,48,49. This new perspective replaces an earlier view in which behavioural
problems in children with epilepsy were explained solely on the basis of seizure and treatment
variables. Nevertheless, many of the interactions between biological and environmental factors
are incompletely understood, especially in children with pre-existing neurological disorders.
The large list of variables that need to be taken into consideration as possible confounding
variables necessitates caution on the part of investigators who are designing or analysing
studies in this area. Few clinical trials for example, except those completed in the last decade,
have stratified or otherwise adjusted for these variables. Despite the lower prevalence of
behavioural problems reported in developing country trials, there is no evidence for an excess
of behavioural problems in children with epilepsy treated with PB.
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Given the current understanding of PB's neurobehavioural adverse effect profile, what are
the most promising areas for its use in wealthy and poor societies?
In Western countries, cost is not generally an issue to the end-user, partly because there is not
a huge difference in cost between PB and some of the older alternatives. Efficacy and
tolerability generally outweigh economic considerations, and a much broader range of
treatment options is available. Realistically, PB is unlikely to return as a first-line AED.
However, PB continues to be employed as a tertiary adjunctive therapy in patients who do not
achieve seizure remission on monotherapy. This is most likely the area in which PB's use will
be increasingly considered. PB's story resembles that of felbamate: initially viewed as a useful
first line AED, withdrawn because of (fatal rare) adverse effects, and now reinstated as a
treatment for intractable epilepsy. Two other indications that are not considered in this review
include infantile epilepsies and convulsive status epilepticus. PB has an established role in
these clinical scenarios.
The decision matrix for treating epilepsy in poor sectors of developing countries is vastly
different to that in affluent sectors of Western countries. In developing countries, the
overwhelming priority is to retain the patient in treatment through a reasonably long period.
This mandates low-cost and accessible treatment50. PB is without doubt the most widely
available and cheapest AED in the world, and clinical trials above, as well as those conducted
in adults, show it is well tolerated in developing country contexts. Long term safety, in terms
of cognitive performance, cannot be judged on the available evidence. However, this potential
disadvantage may be considered an acceptable trade-off against the option of helping a person
with epilepsy integrate more fully into the social and economic life of their community.
Balancing these kinds of quality-of-life issues is difficult to translate for Western audiences
because of the enormous differences in context. PB is therefore likely to maintain its lead as a
first-line AED in developing countries, at least until other AEDs reach a similar standard of
cost, distribution and familiarity amongst primary care providers. At present, newer AEDs are
not widely available in developing countries, although clearly there is a need for a choice of
treatment options.
What research questions need to be addressed to release more of its commercial potential?
There is not much impetus for research into established, out-of-patent antiepileptic drugs in
Western countries, except when indicated for status epilepticus and for intractable epilepsies.
While a head to head monotherapy clinical trial of PB against newer drugs, using appropriate
outcome measures and well defined childhood epilepsy syndromes, would be logical, there
would likely be much resistance to recruitment in Western countries. Nevertheless, there are
some interesting questions that could be addressed in low cost clinical epidemiological studies
that could prove helpful in focusing the optimum clinical indications for PB.
(a) Most pressing of these is the possibility of cognitive impairment in children with epilepsy
treated with PB monotherapy. Does cognitive impairment only occur in children with epilepsy
treated with PB? If so, what age groups are most vulnerable? Is it reversible after treatment
ceases? Is there interaction with central neurological deficit? Which domains of intellect are
most affected? Can the impact be mitigated by educational intervention? Is there a dose effect?
Does the gain in cognitive function expected in children with more severe epilepsy successfully
controlled with PB outweigh the deficit from treatment? In other words, how does the cost-
benefit of PB vary according to the specific clinical scenario? This body of research would be
most valuable for developing country markets.
(b) In Western countries, while the same questions are relevant, molecular diagnostics might
in the near future be useful in assessing prior risk of adverse effects. Recent studies have put
forward the possibility that allelic variants at pharmacologically relevant genes may increase
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prediction of maximum doses for AEDs, and possibly for so-called “drug resistance” or
toxicity51,52. This field of research may well lead to panels of alleles that could be
simultaneously tested against a patient's DNA to predict the risk of adverse effects. This could
potentially lead to a new lease of life for PB and many other pharmacologically active agents
that have been on the shelf for many years. However, the sample sizes required for such allelic
association studies would be very large.
Conclusions
Early studies, of questionable quality, on the use of PB in febrile convulsions led to widespread
concern amongst paediatricians and neurologists about its toxicity. This concern became
generalised to PB in its use as an anti-epileptic agent and was accompanied by a flurry of poorly
designed, seemingly confirmatory studies. Despite better quality recent trials showing no
evidence of excessive behavioural problems using PB for epilepsy, the debate over the routine
use of PB in Western countries was superseded by the advent of new generations of AEDs.
However, public concern over the safety of newer AEDs, and newer pharmacological agents
in general, has prompted a re-evaluation of tried and tested older agents. Although this
pendulum may soon swing back in the opposite direction, there is a real prospect of molecular
biological advances permitting tailored prescribing of both new and older agents with lower
risks of adverse effects. It is important to remember though, that large scale clinical studies
will still be necessary to associate genotypes with toxicity and other outcome phenotypes.
The extreme contrast of health care accessibility for and social attitudes towards epilepsy in
developing countries is often hard to comprehend in Western countries. These differences
greatly influence the trade-offs between seizure control and toxicity that are accepted by
patients, their families and their health care providers. Added to this are potential differences
in biological, and more importantly, environmental factors that bear upon the behavioural and
cognitive outcomes that we have selected as the topic of this review. In these contexts, cost is
king, and PB retains the crown of antiepileptic drugs. PB will remain largely unchallenged
until newer AEDs become more accessible. Interestingly though, the kind of clinical
epidemiological studies suggested above for optimising PB's indications may simultaneously
be valuable in developing molecular biological diagnostics for wealthier markets.
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